Patents by Inventor Matthew ZHOU

Matthew ZHOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11426732
    Abstract: Flow cell devices, cartridges, and systems are described that provide reduced manufacturing complexity, lowered consumable costs, and flexible system throughput for nucleic acid sequencing and other chemical or biological analysis applications. The flow cell device can include a capillary flow cell device or a microfluidic flow cell device.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: August 30, 2022
    Assignee: ELEMENT BIOSCIENCES, INC.
    Inventors: Minghao Guo, Leon Zilun Zhang, Chunhong Zhou, Matthew Kellinger, Michael Previte
  • Patent number: 11407897
    Abstract: Multicomponent copolymers including two or more types of repeat units is presented. In one example, the multicomponent copolymer includes at least one repeat unit AC having a structure (I), at least one repeat unit DC having a structure (II), and at least one repeat unit BC having a structure (III) or (V). The multicomponent copolymer may be cross-linked via a cross-linking agent. A polymer blend including the multicomponent copolymer or a cross-linked copolymer and a second polymer is also provided. The multicomponent copolymer may be a random or a block copolymer. The structural units of the multicomponent copolymers provide improved, tunable properties, such as improved biocompatibility and hydrophilicity, protein fouling, and mechanical properties, to the copolymers and/or the membranes fabricated from the copolymers.
    Type: Grant
    Filed: November 30, 2020
    Date of Patent: August 9, 2022
    Assignee: CYTIVA SWEDEN AB
    Inventors: David Moore, Matthew Jeremiah Misner, Hongyi Zhou, Patrick McCloskey, Matthew Rainka
  • Patent number: 11396198
    Abstract: The present disclosure is drawn to embossed print media including a media substrate having a front side and a back side, an embossed image-receiving layer formed on the front side of the media substrate at a coating weight of 3 gsm to 50 gsm, and a fabric liner coupled to the back side of media substrate via an adhesive layer. The embossed image-receiving layer can include a first pigment filler and a first polymeric binder. The adhesive layer can be applied at a coating weight from 20 gsm to 40 gsm and can include a second polymeric binder and a flame-retarding filler.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: July 26, 2022
    Assignee: Hewlett-Packard Development Company, L.P.
    Inventors: Xiaoqi Zhou, Xulong Fu, Fredrick Muya Makau, Matthew D. Nuth
  • Publication number: 20220226492
    Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds human epidermal growth factor receptor 2 (“HER2”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 21, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
  • Publication number: 20220226491
    Abstract: The invention provides an immunoconjugate of formula (I) or (II). Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds programmed death-ligand 1 (PD-L1) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 21, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
  • Patent number: 11383649
    Abstract: A vehicle includes a vehicle body and storage compartments that are located in the vehicle body. Each of the storage compartments has a cavity and a closure that selectively secures the cavity. A respective authorization input is associated with each of the storage compartments. The closure of each of the storage compartments is operable to unsecure the cavity upon receipt of the respective authorization input.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: July 12, 2022
    Assignee: Apple Inc.
    Inventors: Malcolm J. Northcott, Matthew E. Last, Kan Zhou, David P. Perner
  • Publication number: 20220216321
    Abstract: Redox gating, intrinsically apart from conventional electrolyte gating, combines reversible redox functionalities with common ionic electrolyte moieties to engineer charge transport for power efficient phase control. A colossal sheet carrier density modulation beyond 1016/cm2 as well as up to thousand durable cycling can be reached at the subvolt regime in archetypical functional oxide thin films without unbridled perturbations from ionic defects, which include either cation/anion vacancy or ionic intercalated species like proton. Besides, the redox gating represents a simply and practical way to decouple the electrical and structural phase transitions, improving the device longevity and operation response time. The redox gating works for a wide variety of materials regardless of its crystallinity or crystallographic orientation, including all other functional heterostructures and low-dimensional quantum materials composed of sustainable elements.
    Type: Application
    Filed: January 4, 2021
    Publication date: July 7, 2022
    Inventors: Wei Chen, Matthew Tirrell, Hua Zhou, Le Zhang, Hui Cao, Changjiang Liu
  • Patent number: 11380078
    Abstract: System and method are provided for scaling a 3-D representation of a building structure. The method includes obtaining images of the building structure, including non-camera anchors. The method also includes identifying reference poses for images based on the non-camera anchors. The method also includes obtaining world map data including real-world poses for the images. The method also includes selecting candidate poses from the real-world poses based on corresponding reference poses. The method also includes calculating a scaling factor for a 3-D representation of the building structure based on correlating the reference poses with the selected candidate poses. Some implementations use structure from motion techniques or LiDAR, in addition to augmented reality frameworks, for scaling the 3-D representations of the building structure. In some implementations, the world map data includes environmental data, such as illumination data, and the method includes generating or displaying the 3-D representation.
    Type: Grant
    Filed: December 10, 2020
    Date of Patent: July 5, 2022
    Assignee: HOVER, INC.
    Inventors: Manish Upendran, William Castillo, Jena Dzitsiuk, Yunwen Zhou, Matthew Thomas
  • Publication number: 20220195066
    Abstract: The invention provides immunoconjugates of Formula I comprising an anti-CEA antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.
    Type: Application
    Filed: December 9, 2021
    Publication date: June 23, 2022
    Applicant: BOLT BIOTHERAPEUTICS, INC.
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou
  • Publication number: 20220152215
    Abstract: The invention provides an immunoconjugate of formula (I) or (II) Antibody-adjuvant immunoconjugates of the invention, comprising an antibody construct that has an antigen binding domain that binds carcinoembryonic antigen (“CEA”) linked to one or more adjuvants, demonstrate superior pharmacological properties over conventional antibody conjugates. The invention further provides compositions comprising and methods of treating cancer with the immunoconjugate.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 19, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Marcin Kowanetz, Romas Kudirka, Arthur Lee, William Mallet, Brian Safina, Matthew Zhou, Edgar George Engleman
  • Publication number: 20220143012
    Abstract: The invention provides a macromolecule-supported compound of formula (I) or (II). Macromolecule-supported compounds of the invention, comprising macromolecular support linked to one or more TLR agonists, are recognized by TLRs (e.g., TLR7 and/or TLR8) with high affinity providing utility in therapeutics, diagnostics, and chemical assays. The invention further provides compositions comprising and methods of treating cancer with the macromolecule-supported compounds.
    Type: Application
    Filed: March 13, 2020
    Publication date: May 12, 2022
    Applicants: Bolt Biotherapeutics, Inc., The Board of Trustees of The Leland Stanford Junior University
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, David Dornan, Justin Kenkel, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou, Edgar George Engleman
  • Publication number: 20200390899
    Abstract: The invention provides immunoconjugates of Formula I or III comprising an antibody linked by conjugation to one or more aminobenzazepine derivatives. The invention also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Applicant: BOLT BIOTHERAPEUTICS, INC.
    Inventors: Shelley Erin Ackerman, Michael N. Alonso, Romas Kudirka, Arthur Lee, Brian Safina, Matthew Zhou
  • Publication number: 20200140556
    Abstract: Provided are methods and compositions for treating an individual with cancer or infectious disease. Multivalent Dectin-2 stimulating agents are provided that include: (a) an agent that binds to Dectin-2 and stimulates Dectin-2 signaling; and (b) an antibody and/or an immunomodulatory agent, wherein (a) and (b) are conjugated to one another. In some cases, (a) is a mannobiose glycopolypeptide that binds to Dectin-2. In some cases (b) is a stimulatory ligand for a TLR (e.g., TLR7, TLR8, TLR7/8, TLR2, and the like). Methods of treating an individual with cancer and/or an infectious disease can include administering to the individual an effective amount of a Dectin-2 stimulating composition. In some cases, the Dectin-2 stimulating composition comprises a Dectin-2 stimulating glycopolymer. In some cases the Dectin-2 stimulating composition comprises a multivalent Dectin-2 stimulating agent.
    Type: Application
    Filed: June 27, 2018
    Publication date: May 7, 2020
    Inventors: Justin KENKEL, Matthew ZHOU, Shelley Erin ACKERMAN, Edgar George ENGLEMAN, Michael Nathaniel ALONSO, Carolyn R. BERTOZZI